Fdg Uptake Predicts Recurrence And Survival In Patients With Unresectable Stage Iii Non-Small Cell Lung Cancer Treated With 74 Gy (Rbe) Proton Therapy And Chemotherapy
zuolin xiang,h wen,e jeremy,michael oreilly,ritsuko komaki,james d cox,joe y chang
DOI: https://doi.org/10.1016/j.ijrobp.2011.06.105
2011-01-01
Abstract:To determine if maximum standardized uptake values (SUVmax) from 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/CT (PET/CT) predict time to local recurrence (LR), distant metastasis (DM), progression-free survival (PFS), and overall survival (OS) after concurrent proton therapy and chemotherapy for unresectable Stage III Non-small cell lung cancer (NSCLC). Eighty-four consecutive patients were enrolled and treated with 74 Gy (RBE) passive scattering proton therapy with carboplatin and paclitaxel chemotherapy. All patients underwent 4D-CT-based treatment simulation and re-simulation during proton therapy for potential adaptive re-planning. The 18F-FDG PET/CT scans were obtained from all patients within 1-6 months before (SUV1) and after chemoradiotherapy (SUV2); the delta (Δ)SUV was calculated by subtracting SUV2 from SUV1. SUV cutoff values were identified by receiver operating characteristic analysis. The ability of SUV1, SUV2, ΔSUV, and other clinicopathologic factors to predict LR, DM, PFS, and OS was estimated with univariate and multivariate Cox regression analyses. At a median follow-up time of 19.2 months (range, 6.1-52.4 months), 14 patients (17%) had LR, 7 (8%) had lymph node recurrence outside the planning target volume, and 33 (39%) had DM. The median survival time was 29.9 months, and 48 patients (57%) were alive at the time of analysis. An SUV2 cutoff value of 4.4 was found to predict LR (area under the curve [AUC], 0.691, 95% confidence interval [CI], 0.505-0.877; p = 0.031); an SUV1 cutoff value of 11.9 and an SUV2 cutoff value of 4.4 were found to predict OS (AUC, 0.654; 95% CI, 0.527-0.780; p = 0.023; and AUC 0.723; 95% CI, 0.597-0.849; p = 0.001). Of 12 clinicopathologic features evaluated in univariate analysis (age, sex, performance status, smoking status, tumor histology, gross tumor volume, lung V20, mean lung dose, SUV1, SUV2, ΔSUV, and ΔSUV/SUV1), only SUV1 (p = 0.003) and SUV2 (p < 0.001) predicted LR-free survival (LRFS). SUV1, SUV2, and performance status predicted DM-free survival (DMFS), PFS, and OS (p = 0.049∼0.001). Multivariate survival analysis showed that SUV2 (p = 0.006) was independently prognostic for LRFS; SUV1, SUV2, and performance status were independently prognostic for DMFS and PFS (p = 0.035∼0.010); and SUV2 (p = 0.011) and performance status (p = 0.001) were independently prognostic for OS. High-dose proton therapy with chemotherapy produced a local control rate of >80% and 29.9 months median survival in patients with unresectable Stage III NSCLC. SUV2 was an important independent prognostic factor for LRFS, DMFS, PFS, and OS; SUV1 was independently prognostic for DMFS and PFS.